Yahoo
NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

208.90 -0.29 (-0.14%)
As of 11:51:15 AM EST. Market Open.
Trade BDX on Coinbase
BDX Q4 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for BDX

What's happening with BDX?

18m ago
Powered by Yahoo Scout

Becton Dickinson reported fiscal fourth-quarter revenue of $5.27 billionand adjusted EPS (earnings per share) of $4.15, beating analyst estimates on both measures. The quarter showed strength in Interventional and select medication-delivery businesses, while Medical Essentials declined sharply. Management also raised the dividend and authorized 10 million additional share repurchases.

Powered by Yahoo Scout
  • Previous Close 209.19
  • Open 208.00
  • Bid 209.81 x 10000
  • Ask 210.21 x 20000
  • Day's Range 206.50 - 214.78
  • 52 Week Range 127.59 - 214.78
  • Volume 1,458,891
  • Avg. Volume 1,770,378
  • Market Cap (intraday) 56.9B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 48.58
  • EPS (TTM) 4.30
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield 4.20 (2.01%)
  • 1y Target Est 195.57
  • Morningstar Rating Rating available with Stock Picks access

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

72,000

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BDX
39.58%
S&P 500 (^GSPC)
8.82%

1-Year Return

BDX
54.41%
S&P 500 (^GSPC)
9.61%

3-Year Return

BDX
9.15%
S&P 500 (^GSPC)
70.92%

5-Year Return

BDX
22.25%
S&P 500 (^GSPC)
58.58%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 5.27B
Earnings 696M
Profit Margin 13.20%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
1B
2B
3B
4B
5B
-5.0%
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

165.00 Low
195.57 Average
208.90 Current
225.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/7/2026
Analyst Barclays
Rating Action Initiated
Rating Underweight
Price Action Announces
Price Target 165

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.19%

  • Return on Assets (ttm)

    4.34%

  • Return on Equity (ttm)

    6.61%

  • Revenue (ttm)

    22.48B

  • Net Income Avi to Common (ttm)

    1.65B

  • Diluted EPS (ttm)

    4.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    709M

  • Total Debt/Equity (mrq)

    68.84%

  • Levered Free Cash Flow (ttm)

    4.48B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: